Skip to main content
    B

    Bicycle Therapeutics Ltd (BCYC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.18
    -0.19 (-5.64%)

    Market Cap: $236.22M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Bicycle Therapeutics Ltd (BCYC) Financials: Revenue, Profit and Cash Flow

    Updated Oct 29, 2026. Financial statements from company filings, amounts in US dollars.

    Bicycle Therapeutics reported revenue of $72.59M for the fiscal year ended Dec 31, 2025, up 105.8% from the year before. That year, net income was -$218.96M with a net margin of -301.7%, operating cash flow was -$249.68M and free cash flow was -$252.03M. The quarter ended Sep 30, 2026 had revenue of $34.06M and net income of -$10.48M.

    Revenue and Margins

    Over the 8 years to Dec 2025, revenue grew from $2.06M, a compound annual rate of 56.1%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$72.59M+105.8%100.0%-341.3%-301.7%
    Dec 2024$35.27M+30.8%-390.3%-595.0%-479.2%
    Dec 2023$26.98M+86.5%-480.1%-704.1%-669.7%
    Dec 2022$14.46M+23.6%100.0%-806.6%-779.3%
    Dec 2021$11.70M+12.6%100.0%-561.0%-571.2%
    Dec 2020$10.39M-24.7%-219.0%-500.1%-491.0%
    Dec 2019$13.80M+93.4%100.0%-190.6%-221.8%
    Dec 2018$7.14M+246.4%-190.9%-304.7%-306.1%
    Dec 2017$2.06MN/A-476.0%-787.0%-789.3%
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$72.59M$35.27M$26.98M$14.46M$11.70M$10.39M$13.80M$7.14M$2.06M$0
    Cost of revenue$6.44M$172.97M$156.50M$3.69M$44.88M$33.15M$25.54M$20.76M$11.87M$269.29K
    Gross profit$72.59M-$137.69M-$129.52M$14.46M$11.70M-$22.76M$13.80M-$13.63M-$9.81M-$269.29K
    Research and development$240.28M$172.97M$156.50M$81.61M$44.88M$33.15M$25.54M$20.76M$11.87M$9.77M
    Operating income-$247.72M-$209.87M-$189.95M-$116.65M-$65.62M-$51.96M-$26.30M-$21.75M-$16.21M-$13.49M
    Net income-$218.96M-$169.03M-$180.66M-$112.72M-$66.82M-$51.01M-$30.61M-$21.85M-$16.26M-$13.51M
    EBITDA-$212.18M-$164.89M-$169.40M-$107.21M-$64.09M-$50.68M-$25.34M-$21.53M-$15.88M-$13.26M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$34.06M$629.00K$887.00K$47.95M$11.73M$2.92M$9.98M$3.71M$2.68M$9.36M$19.53M$5.33M
    Gross profit$34.06M$629.00K$887.00K$47.95M$11.73M-$68.11M-$47.29M-$52.36M-$42.97M$9.36M$19.53M$5.33M
    Operating income-$13.48M-$54.56M-$65.59M-$24.66M-$65.55M-$86.60M-$70.20M-$67.66M-$63.85M-$46.65M-$31.72M-$54.23M
    Net income-$10.48M-$50.33M-$60.83M-$20.15M-$59.10M-$78.95M-$60.75M-$51.85M-$50.80M-$39.81M-$26.56M-$49.10M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $2.76M by $625.35M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$717.60M$956.87M$595.34M$410.61M$479.79M$161.15M$110.19M$81.63M$74.00M$11.84M
    Current assets$682.88M$928.61M$561.87M$369.38M$458.56M$155.72M$104.15M$76.77M$71.51M$11.29M
    Cash and equivalents$628.11M$879.52M$526.42M$339.15M$438.68M$135.99M$92.12M$63.38M$67.66M$9.40M
    Total liabilities$107.62M$163.81M$224.41M$139.83M$133.54M$65.69M$17.00M$151.45M$121.19M$3.81M
    Short-term debt$2.76M$5.50M$4.88M$3.13M$2.38M$844.00K$640.00K$15.00K$3.26M$0
    Long-term debtN/AN/A$30.70M$30.32M$29.87M$14.51MN/A$0$0$0
    Shareholder equity$609.98M$793.06M$370.93M$270.78M$346.25M$95.46M$93.20M-$69.83M-$47.18M$8.02M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$567.18M$606.58M$652.40M$717.60M$763.95M$832.18M$883.89M$956.87M$996.75M$1.06B$547.14M$595.34M
    Total liabilities$61.90M$96.32M$98.08M$107.62M$145.47M$163.27M$143.56M$163.81M$165.71M$183.54M$191.09M$224.41M
    Cash and equivalents$469.93M$510.05M$559.47M$628.11M$648.33M$721.45M$792.97M$879.52M$890.86M$961.36M$457.00M$526.42M
    Shareholder equity$505.28M$510.25M$554.32M$609.98M$618.48M$668.91M$740.33M$793.06M$831.03M$873.81M$356.05M$370.93M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$249.68M-$164.72M-$60.63M-$86.11M-$14.79M-$17.79M-$28.61M-$26.08M-$1.42M-$11.27M
    Capital expenditures$2.36M$1.24M$2.93M$18.99M$2.03M$1.20M$1.55M$1.19M$1.11M$243.36K
    Free cash flow-$252.03M-$165.96M-$63.56M-$105.10M-$16.82M-$18.99M-$30.17M-$27.26M-$2.53M-$11.51M
    Investing cash flow-$2.35M-$1.24M-$2.93M-$18.99M-$2.03M-$1.20M-$1.55M-$1.19M-$1.11M-$243.36K
    Financing cash flow-$131.00K$519.75M$250.03M$6.69M$320.73M$62.84M$58.44M$25.43M$57.88M$16.77M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$40.30M-$49.61M-$65.92M-$19.01M-$71.17M-$72.79M-$86.70M-$9.40M-$39.83M-$44.70M-$70.83M-$47.29M
    Capital expenditures$305.00K$265.00K$713.00K$574.00K$674.00K$498.00K$606.32K$368.00K$434.87K$420.14K$11.99K$51.00K
    Free cash flow-$40.61M-$49.87M-$66.64M-$19.59M-$71.85M-$73.28M-$87.31M-$9.76M-$40.27M-$45.12M-$70.84M-$47.34M
    Last 12 quarters

    Frequently Asked Questions About BCYC

    What is Bicycle Therapeutics' annual revenue?

    Bicycle Therapeutics reported revenue of $72.59M for the fiscal year ended Dec 31, 2025.

    How fast is Bicycle Therapeutics' revenue growing?

    Revenue was up 105.8% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 71.2%.

    Is Bicycle Therapeutics profitable?

    No. Bicycle Therapeutics reported net income of -$218.96M for the fiscal year ended Dec 31, 2025, with a net margin of -301.7%.

    How much free cash flow does BCYC generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$249.68M minus capital expenditures of $2.36M produced free cash flow of -$252.03M.

    How much debt does Bicycle Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $2.76M and cash and equivalents of $628.11M.